ライフサイエンスコーパス: athymic

1 Newborn screening detects patients with athymic 22q11 deletion syndrome, but significant illness

2 ctive at suppressing tumor outgrowth in both athymic and Ido1-deficient mice, providing in vivo corro

3 munological patterns are recognized, namely, athymic and incomplete 22q11 deletion syndrome and autoi

4 e also show that Macrocyclon is effective in athymic and major histocompatibility complex class II-/-

5 oformans infection in FcRgammaIII-deficient, athymic, and SCID mice significantly increased IFN-gamma

6 BL/6J mice but not in FcRgammaIII-deficient, athymic, and SCID mice.

7 The numbers of organisms in the athymic animals increased markedly after cyclophosphamid

8 onic carcinoma microcolonies were induced in athymic BALB/c mice by intravenous injection of 100 muL

9 Groups of athymic BALB/c mice with subcutaneous CAIX-positive SK-R

10 Additional experiments using female athymic BALB/c nu/nu mice showed that p.o. administratio

11 aneously implanting human thymus tissue into athymic C57BL/6 nude mice.

12 to castration-recurrent CWR22R tumor-bearing athymic castrated male mice produced a 28-fold increase

13 Athymic CD1 nu/nu mice bearing subcutaneous trastuzumab-

14 In contrast, p65KO athymic chimeric mice with human GBM, failed to inhibit

15 is a promising strategy for the treatment of athymic complete DiGeorge syndrome (cDGS).

16 Thymus allograft biopsies were performed in athymic infants with complete DiGeorge anomaly after thy

17 eorge anomaly refers to the subgroup that is athymic (< 1%).

18 tumor xenograft subcutaneously implanted in athymic male nude mice.

19 P-alb/UL39 transfection, were established in athymic mice (n = 28) and treated with G207.

20 same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes).

21 en-independent relapsed tumors (104-Rrel) in athymic mice after castration.

22 nced regression of PSMA-expressing tumors in athymic mice after systemic administration.

23 g the growth of breast cancer tumors in CD-1 athymic mice and caused no normal organ toxicity.

24 colony formation, xenograft-tumor growth in athymic mice and invasion.

25 ibroblasts were implanted intradermally into athymic mice and tissue formation was analyzed over time

26 neomycin inhibited PC-3 cell tumor growth in athymic mice and was accompanied by a decrease in both c

27 s were administered at 5 mg/kg i.p. daily in athymic mice bearing 1483 human SCCHN xenografts alone o

28 ) was administered by tail vein injection to athymic mice bearing disseminated murine myeloid leukemi

29 both the B16 murine model of melanoma and in athymic mice bearing human A375 xenografts.

30 Athymic mice bearing human prostate cancer xenografts we

31 To identify such biomarkers, athymic mice bearing L2987 human tumor xenografts were t

32 In vivo SPECT imaging was performed using athymic mice bearing MDA-MB-468 or HT1080 xenografts and

33 ing studies with (18)F-TFB were performed in athymic mice bearing NIS-expressing C6-glioma subcutaneo

34 gonists also inhibit tumor growth in vivo in athymic mice bearing Panc-28 cell xenografts.

35 Athymic mice bearing Ramos lymphoma xenografts received

36 Athymic mice bearing Ramos lymphoma xenografts received

37 K and 64Cu-TETA-SCK-folate were evaluated in athymic mice bearing small-size KB cell xenografts (10-1

38 -NT-AuNP was injected intratumorally in CD-1 athymic mice bearing subcutaneous EGFR-positive MDA-MB-4

39 4-EGF was studied at 48 h after injection in athymic mice bearing subcutaneous MDA-MB-231/H2N tumors.

40 nd normal-tissue uptake were examined in CD1 athymic mice bearing subcutaneous tumor xenografts that

41 Treatment of athymic mice bearing TAMH flank tumors with vehicle or P

42 These studies were done in ovariectomized, athymic mice bearing tumors of estrogen receptor-positiv

43 activate p53 in colorectal cancers grown in athymic mice by augmenting phosphorylation of p53 at ser

44 ariants were evaluated in LS174T xenografted athymic mice by small animal positron emission tomograph

45 Diabetes was induced in nude athymic mice by streptozotocin injections.

46 ll lines tested, and in the tumors formed in athymic mice by these cell lines.

47 ted vessel formation in Matrigel implants in athymic mice by utilizing GFP imaging or magnetic resona

48 Preclinical studies using athymic mice carrying human tumor xenografts also inform

49 al analysis of OSCC tumors that developed in athymic mice demonstrated RANKL and NFATc3 expression in

50 BMP4 in cell culture and implanted s.c. into athymic mice develop into tissue indistinguishable from

51 In contrast, athymic mice did not develop HIT-like antibodies.

52 Interestingly, injection of VR cells into athymic mice formed malignant ascites in 100% of the ani

53 transplantation, thymus-grafted congenitally athymic mice frequently develop multiorgan autoimmunity.

54 ing of NVP-AUY922 (50 mg/kg i.p. or i.v.) to athymic mice generated peak tumor levels at least 100-fo

55 Tumors in athymic mice implanted s.c. with GH3 cells resulted in w

56 led UA20 and N3M2 scFvs were administered to athymic mice implanted subcutaneously with DU145 cells.

57 tant form of sGC (sGCalpha1beta1(Cys105)) in athymic mice increased the survival time by 4-fold over

58 of beta-catenin-deficient chondrocytes into athymic mice persisted for a longer period of time and r

59 Athymic mice rendered leukopenic with cyclophosphamide b

60 pha-expressing human osteosarcoma cells into athymic mice resulted in larger and more frequent lung m

61 Adoptive transfer of these T cells to athymic mice resulted in T-cell infiltration of the gut,

62 nes that overexpress Tiam1 into the cecum of athymic mice resulted in tumor growth in the spleen, liv

63 nd evaluate their ability to image tumors in athymic mice that express one or both receptors using sm

64 Moreover, athymic mice that lacked GPC1 exhibited decreased tumor

65 amos, Raji, and FL-18 lymphoma xenografts in athymic mice to assess the potential for improving the e

66 ma cells, was first injected into 5-week-old athymic mice to confirm and compare GRP78 expression in

67 ime PCR in human biopsies and in tumors from athymic mice treated with saline, histamine, histidine d

68 Xenograft tumors were developed in athymic mice using MCA207 cells expressing green fluores

69 in-4-positive MDA-MB-468 xenograft tumors in athymic mice was significantly higher than in (111)In-GS

70 tion of PEITC to the PC-3 tumor-bearing male athymic mice were accompanied by statistically significa

71 Athymic mice were found to be markedly resistant to all

72 Athymic mice were inoculated with A375M melanoma cells.

73 Fifteen athymic mice were treated intravenously with saline (n =

74 umors derived from U87 human glioma cells in athymic mice were treated with oncolytic HSVs G207 or G4

75 -infrared) and injected intravenously into 6 athymic mice which were inoculated orthotopically with g

76 These cell lines form fibrosarcomas in athymic mice with a very short latency, and the cells fr

77 Athymic mice with implanted human MV522 tumors were trea

78 ed of these bacteria even in immunodeficient athymic mice with no apparent side effects.

79 Athymic mice with tumors resulting from injection of A54

80 the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.

81 ty and apoptosis against SKOV3 xenografts in athymic mice without significant weight loss or cytotoxi

82 eries of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibi

83 tes were grafted on full-thickness wounds in athymic mice, and biopsy samples for microarray analyses

84 n vivo, Mz-ChA-1 cells were s.c. injected in athymic mice, and the effects of GABA on tumor size, tum

85 tion and absence of organisms in the skin of athymic mice, compared with euthymic ones.

86 etastasis, cancer cells were inoculated into athymic mice, either into femoral bone marrow cavities o

87 When implanted in athymic mice, HYAL1-v1-expressing tumors grew 3- to 4-fo

88 mber of human tumor xenografts grown s.c. in athymic mice, including H460 human lung carcinoma, Colo2

89 This response to treatment was lost in athymic mice, indicating a requirement for active host T

90 unocompetent C57BL/6 but not immunodeficient athymic mice, leading to specific immune memory against

91 After intradermal injection into athymic mice, only fibroblasts expressing active TGF-bet

92 glioma-bearing immunocompetent mice, but not athymic mice, resulted in prolonged survival, suggesting

93 In athymic mice, SCC-S2 transfectants showed significantly

94 rmal and serum cytokine levels in normal and athymic mice, suggesting that T cells play a negligible

95 Following intravenous administration to athymic mice, the (111)In complex of 1 was found to sele

96 When injected into athymic mice, these cell lines with near normal levels o

97 n a human prostate adenocarcinoma growing in athymic mice, using near infrared (NIR) dyes as model mo

98 A-deficient cells formed tumors in castrated athymic mice, whereas LNCaP did not.

99 52 cells, as assayed by s.c. tumor growth in athymic mice, whereas silencing Smad3 alone did not indu

100 -kappaB activity exhibit decreased growth in athymic mice, which was further reduced by IR with downr

101 Rgamma, when transplanted into the dorsum of athymic mice.

102 tablished HER2-positive BT-474 xenografts in athymic mice.

103 , leading to the formation of large tumor in athymic mice.

104 T-474) following Ang-(1-7) administration to athymic mice.

105 m tumors when implanted into the fat pads of athymic mice.

106 of tumor cells in vitro and in congenitally athymic mice.

107 ast PET images of colon cancer xenografts in athymic mice.

108 (125)I, (111)In, or (64)Cu in tumor-bearing athymic mice.

109 f 54%), compared with that of PC3V tumors in athymic mice.

110 t survival of HeLa cells in soft agar and in athymic mice.

111 more neutrophils and ingested bacilli in the athymic mice.

112 colon adenocarcinoma xenografts implanted in athymic mice.

113 rated tumors when injected subcutaneously in athymic mice.

114 its antitumor effects in xenograft models in athymic mice.

115 stage colon carcinoma, are nontumorigenic in athymic mice.

116 micrometastasis by 4 weeks in >80% of inbred athymic mice.

117 of H-Ras-transformed cells to form tumors in athymic mice.

118 afts of human colon and pancreatic tumors in athymic mice.

119 tion in xenografts when administered p.o. to athymic mice.

120 n reduced levels of serum, or form tumors in athymic mice.

121 antly inhibited RCC 786-O tumor formation in athymic mice.

122 asis when these cells were transplanted into athymic mice.

123 nd growth as soft agar colonies or tumors in athymic mice.

124 mation in soft agar, and xenograft growth in athymic mice.

125 the ability of these cells to form tumors in athymic mice.

126 ucted with human breast cancer xenografts in athymic mice.

127 in culture or 3T3-F442A cells implanted into athymic mice.

128 owth, invasion, and metastatic efficiency in athymic mice.

129 these cells to form pulmonary metastases in athymic mice.

130 transplanting human bioengineered skin onto athymic mice.

131 owth of xenografted tumors and metastasis in athymic mice.

132 human lung carcinoma xenografts implanted in athymic mice.

133 ed of these bacteria even in immunodeficient athymic mice.

134 carcinoma LS174T grown as s.c. xenografts in athymic mice.

135 transferring immune cells from these mice to athymic mice.

136 an prostate tumor, CWR22, was implanted into athymic mice.

137 ehavior of the tumors that they generated in athymic mice.

138 their ability to migrate to the skeletons of athymic mice.

139 tumors were implanted subcutaneously in six athymic mice.

140 d orthotopically to full-thickness wounds on athymic mice.

141 and in vivo using human tumor xenografts in athymic mice.

142 sion and metastasis of human cancer cells in athymic mice.

143 hondrocytes, and implanted subcutaneously in athymic mice.

144 as well as tumor growth when inoculated into athymic mice.

145 an behave as a T-cell-independent antigen in athymic mice; (iv) the rodent core proteins are not sign

146 Using an athymic mouse model of endometriosis, we now report that

147 We confirmed the approach in an athymic mouse model of metastatic human breast cancer by

148 y leads to a complete tumor regression in an athymic mouse tumor xenograft model, it fails to do so i

149 to abraded skin on the muzzles and tails of athymic NCr nude mice.

150 istribution studies in female ovariectomized athymic (NCr) nu/nu mice bearing GPR30-expressing human

151 enhancement in the median survival (17%) of athymic nu/nu mice bearing NCI-H460 tumor xenografts.

152 ImmunoPET in male athymic nu/nu mice bearing subcutaneous LNCaP (PSMA-posi

153 vitro and was localized to tumor tissues in athymic nu/nu mice implanted with CCK2R-expressing tumor

154 sted from the footpads of M. leprae-infected athymic nu/nu mice, were cocultured with normal or IFN-g

155 urface epithelial cells and NIH 3T3 cells in athymic nu/nu mice.

156 alphabeta T cells in the lymphoid tissues of athymic nu/nu mice.

157 tional T cells via an extrathymic pathway in athymic nu/nu mice.

158 -induced angiogenesis and tumor formation in athymic nu/nu mice.

159 K1-induced angiogenesis and tumorigenesis in athymic nu/nu mice.

160 relatively thymus deficient, we used C57BL/6 athymic nude and euthymic mice to evaluate the relations

161 These experiments demonstrate that athymic nude C57BL/6 mice are markedly resistant to expe

162 in vivo models of lung cancer metastasis in athymic nude Foxn1(nu) mice.

163 Male athymic nude mice (age 4-6 weeks) were inoculated s.c. w

164 , caused rapid tumor formation and growth in athymic nude mice after subcutaneous inoculation of the

165 ction of an IL-6-expressing CHO-cell line in athymic nude mice and by osmotic mini-pump delivery of r

166 the growth of human PaC tumors propagated in athymic nude mice and caused modulation of cFLIP and TRA

167 00-fold reduction in lethality of vaccinated athymic nude mice and induced severalfold-higher cellula

168 for PET imaging of experimental human PC in athymic nude mice and spontaneously grown PC in transgen

169 but failed to inhibit Renca tumor growth in athymic nude mice and that SSG treatment of T cells in v

170 can suppress growth of lung cancer cells in athymic nude mice and this requires its DUB activity.

171 to HCT116 colon adenocarcinoma xenografts in athymic nude mice and tumor volume was measured.

172 Athymic nude mice are neutropenic or have near-normal ne

173 Athymic nude mice bearing (V600E)BRAF-expressing human C

174 all-animal PET experiments were performed in athymic nude mice bearing a BON-1 tumor xenograft.

175 h (18)F-FHNP and (18)F-FES were conducted in athymic nude mice bearing a SKOV3 xenografts.

176 PET imaging experiments were performed with athymic nude mice bearing A33 antigen-expressing, SW1222

177 en-dependent SSM3 mouse mammary tumors, male athymic nude mice bearing androgen-dependent CWR22 prost

178 state cancer xenografts, and male and female athymic nude mice bearing estrogen-independent MDA-MB-23

179 When injected intravenously into the BALB/c athymic nude mice bearing folate receptor (FR)-overexpre

180 For in vivo characterization, athymic nude mice bearing HER2-overexpressing SKBr3-luc

181 /kg doxorubicin rapidly eradicated tumors in athymic nude mice bearing KB or MIA Paca-2 xenografts.

182 cumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and th

183 Athymic nude mice bearing MDA-MB-435 xenografts were tre

184 (25 mg/kg/d) also inhibited tumor growth in athymic nude mice bearing RKO cell xenografts.

185 Biodistribution studies in athymic nude mice bearing s.c. neuroblastoma (IMR-6, NMB

186 or expression, we administered the tracer to athymic nude mice bearing subcutaneous human breast canc

187 ody (18F-FB-T84.66 diabody) was evaluated in athymic nude mice bearing subcutaneous LS 174T human col

188 raphic imaging of (64)Cu-DOTA-[Lys(3)]BBN in athymic nude mice bearing subcutaneous PC-3 and CWR22 tu

189 s of both radiotracers were examined in male athymic nude mice bearing subcutaneous PC-3 tumors by me

190 ntegrin alpha(v)beta(3) expression in female athymic nude mice bearing the subcutaneous UG87MG glioma

191 bution and imaging studies were performed in athymic nude mice bearing U87MG glioma and MDA-MB-435 br

192 istribution studies were performed using the athymic nude mice bearing U87MG human glioma xenografts

193 Cu-L3, and 99mTc-Sestamibi were evaluated in athymic nude mice bearing U87MG human glioma xenografts.

194 the volume of pancreatic tumor xenografts in athymic nude mice by 69.2% (P < 0.01) compared with cont

195 grafts derived from DU-145-Bcl-x(L) cells in athymic nude mice completely eradicated not only primary

196 mda-7 into human breast cancer xenografts in athymic nude mice completely eradicated not only the pri

197 regulatory-T-cell-depleted CD4+ T cells into athymic nude mice each had no effect on either the prima

198 oma cells were inoculated into the flanks of athymic nude mice either alone, or as mixed suspensions

199 5) was evaluated growing as a solid tumor in athymic nude mice for both radiation protocols.

200 uses transplanted into single lymph nodes of athymic nude mice generated functional immune systems th

201 Athymic nude mice had smaller skin lesions that containe

202 nistration of PFE (0.1% and 0.2%, wt/vol) to athymic nude mice implanted with androgen-sensitive CWR2

203 Treatment with fisetin in athymic nude mice implanted with AR-positive CWR22Rupsil

204 Further, athymic nude mice implanted with AsPC-1 cells were treat

205 on in prostate-specific antigen secretion in athymic nude mice implanted with CWR22Rnu1 cells.

206 e growth of mammary tumors in ovariectomized athymic nude mice implanted with estrogen-sensitive brea

207 tment with panobinostat improved survival of athymic nude mice implanted with human CTCL cells.

208 Oral administration of compound 28 to athymic nude mice implanted with human tumor xenografts

209 administration (2 mg, i.p. thrice weekly) to athymic nude mice implanted with PC3 cells resulted in a

210 eration in vitro and reduced tumor burden in athymic nude mice in vivo.

211 . injection of cells with VEGF-A siRNAs into athymic nude mice led to slower-growing tumors, decrease

212 d adoptive transfer of congenic T cells into athymic nude mice prior to infection did not alter lesio

213 t implantation of human RCC tumor cells into athymic nude mice promotes the appearance of VEGF recept

214 man prostate peripheral zone transplanted to athymic nude mice provide a unique model of human angiog

215 tein (GFP), were injected into the spleen of athymic nude mice to establish liver metastases; mice we

216 Diabetic athymic nude mice transplanted with 1500 to 3000 islet e

217 acardiac and direct intratibial injection of athymic nude mice was determined.

218 Tumor development in athymic nude mice was inhibited by 80%.

219 -positive U87MG and MDA-MB-435 tumor-bearing athymic nude mice was measured by both noninvasive micro

220 n breast cancer-mediated osteolysis in vivo, athymic nude mice were inoculated with MDA-MB-231 cells

221 se (luc) gene-expressing Hep3B tumor-bearing athymic nude mice were randomly divided into four groups

222 ited growth of HCC cells xenotransplanted in athymic nude mice when compared to either agent alone.

223 IA PaCa-2 were injected into the pancreas of athymic nude mice, and their local and distant spread wa

224 ures and drastically reduced tumor growth in athymic nude mice, due to down regulation of fibroblast

225 In athymic nude mice, EGFR overexpression enhanced the grow

226 In athymic nude mice, FRA-1, but not the control vector, ra

227 formed fibrosarcomas when injected s.c. into athymic nude mice, whereas almost no tumor formation was

228 been knocked down formed invasive tumors in athymic nude mice, whereas the control cells did not.

229 bited the growth of SCC1 tumor xenografts in athymic nude mice, which was associated with: (i) inhibi

230 into the epithelium-free mammary fat pads of athymic nude mice.

231 ing prostate and breast cancer xenografts in athymic nude mice.

232 uman breast cancer xenograft (MDA-MB-435) in athymic nude mice.

233 liferation and peritoneal tumor formation in athymic nude mice.

234 er in MDA-MB-231 breast cancer tumor-bearing athymic nude mice.

235 ncer models (PC-3 and CWR22) were studied in athymic nude mice.

236 MCF7 breast cancer cell xenograft growth in athymic nude mice.

237 rom adult mice and grafting cell mixtures on athymic nude mice.

238 press tumorigenicity of lung cancer cells in athymic nude mice.

239 uced anovulatory C31F(1) mice and subfertile athymic nude mice.

240 atic cancer cells in soft agar as well as in athymic nude mice.

241 c and subcutaneous xenograft tumor models in athymic nude mice.

242 ression of STRAP increases tumorigenicity in athymic nude mice.

243 bryos and inhibits xenograft tumor growth in athymic nude mice.

244 ith positive selection in both wild-type and athymic nude mice.

245 gar colony formation, and tumor formation in athymic nude mice.

246 cells derived orthotopic xenograft tumors in athymic nude mice.

247 n breast cancer cells in culture and also in athymic nude mice.

248 tratibial injection of tumor cells in female athymic nude mice.

249 e fibroblasts, rendering them tumorigenic in athymic nude mice.

250 al cancer cells in vitro and tumors grown in athymic nude mice.

251 e subcutaneous tumor growth of A549 cells in athymic nude mice.

252 tic cell transformation and tumorigenesis in athymic nude mice.

253 wth of human colon cancer cell xenografts in athymic nude mice.

254 atin-resistant human ovarian cancer cells in athymic nude mice.

255 trol in a A375 human melanoma tumor model in athymic nude mice.

256 treptozotocin-induced 8- to 10-week-old male athymic nude mice.

257 and decreased growth of tumor xenografts in athymic nude mice.

258 is in a colorectal cancer xenograft model in athymic nude mice.

259 odel was not different between wild type and athymic nude mice.

260 morigenic, rapidly producing large tumors in athymic nude mice.

261 of tumorogenic cells and tumor formation in athymic nude mice.

262 xenografting tumor tissue onto the backs of athymic nude mice.

263 d increased the lymph node homing by 144% in athymic nude mice.

264 at two aggressive orthotopic tumor models in athymic nude mice: a human PC-3 M-luc-C6 prostate tumor

265 g activity observed for both 14 and 15 in an athymic nude mouse MDA-MB-231 human breast cancer xenogr

266 All athymic nude mouse strains showed active infections at b

267 of aspirin also inhibited tumor growth in an athymic nude mouse xenograft model.

268 gnitive decline was addressed by irradiating athymic nude rats followed 2 days later by intrahippocam

269 ting radiation-induced cognitive impairment, athymic nude rats subjected to head only irradiation (10

270 s) survived grafting into the spinal cord of athymic nude rats with no signs of overgrowth and with a

271 Similar CpG treatment of athymic nude rats yielded no neuroprotection, further su

272 ally 10 minutes after the induction of MI in athymic nude rats.

273 strains of male and female mice (129S6/SvEv, athymic nude, and BALB/c).

274 ctic procedures into the brains of 37 female athymic nude-Foxn1nu mice and allowed to develop into a

275 gammadelta T cells mediate demyelination in athymic (nude) mice infected with the neurotropic corona

276 a were injected into human skin grafted onto athymic, nude mice.

277 animal model, that immunocompetent, but not athymic, nude rats injected intraperitoneally with xenog

278 rowth in both in vitro and xenograft murine (athymic-nude) models after EerI treatment (p<0.05).

279 for severe combined immunodeficiency detects athymic patients, although diagnosis may be complicated,

280 In the athymic rat, imatinib decreased right ventricular hypert

281 e culture-conditioned media and delivered to athymic rats after ischemia-reperfusion injury.

282 We then induced myocardial infarction in athymic rats and injected 5 million ECs (human umbilical

283 n osteochondral defects of 14 knees of seven athymic rats and were evaluated with magnetic resonance

284 nous annulus fibrosus in the caudal spine of athymic rats for up to 6 mo.

285 12 with human HepG2/C3A cells were tested in athymic rats in a femoral arteriovenous shunt model.

286 231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a

287 Experimental (n=8) and control (n=6) athymic rats underwent intramyocardial injection of up t

288 D2R80A overexpressing hMSC transplanted into athymic rats was performed by PET using (18)F-fallypride

289 -small cell lung cancer xenografts (H460) in athymic rats were imaged with (18)F-EF5 PET before and a

290 animal care and use committee approval, six athymic rats were injected with intravenous ferumoxytol

291 Following C5 hemisections, athymic rats were treated with patches loaded with low a

292 with the non-FR-targeted USPIO P904 and nine athymic rats with implanted FR-negative A549 lung cancer

293 Subsequently, six athymic rats with implanted FR-positive MDA-MB-231 breas

294 Six athymic rats with implanted FR-positive MDA-MB-231 cance

295 When transplanted onto hearts of athymic rats, the human myocardium survives and forms gr

296 in corresponding regions of normal hearts in athymic rats.

297 SC progeny into the left ventricular wall of athymic rats.

298 Extrathymic development in athymic recipients generated conventional naive TCRalpha

299 trathymic T cell development in euthymic and athymic recipients of bone marrow transplantation (BMT).

300 Congenitally athymic Rowett rats received injections of formalin-fixe